ArticleScience translational medicine2014
Lymph node fibroblastic reticular cell transplants show robust therapeutic efficacy in high-mortality murine sepsis.
Article in Science translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 52 citations in OpenAlex.
- Engineered macroporous gelatin scaffolds enhance lymph node fibroblastic reticular cell identity and enable diabetogenic T cell immunomodulation.Biomaterials · 2026Article
- Fibril-Guided Three-Dimensional Assembly of Human Fibroblastic Reticular Cells.ACS applied bio materials · 2024Article
- Activation of TLR9 signaling suppresses the immunomodulating functions of CD55Frontiers in immunology · 2024Article
- Fibroblastic reticular cells provide a supportive niche for lymph node-resident macrophages.European journal of immunology · 2023Article
- FRC transplantation restores lymph node conduit defects in laminin α4-deficient mice.JCI insight · 2023Article
- Nestin+ Peyer's patch resident MSCs enhance healing of inflammatory bowel disease through IL-22-mediated intestinal epithelial repair.Cell proliferation · 2023Article
- Fibroblastic reticular cells mitigate acute GvHD via MHCII-dependent maintenance of regulatory T cells.JCI insight · 2022Article
- NestinInternational journal of molecular sciences · 2022Article
- Lymph node fibroblastic reticular cells preserve a tolerogenic niche in allograft transplantation through laminin α4.The Journal of clinical investigation · 2022Article
- Comparison of Single and Repeated Dosing of Anti-Inflammatory Human Umbilical Cord Mesenchymal Stromal Cells in a Mouse Model of Polymicrobial Sepsis.Stem cell reviews and reports · 2022Article
- Secondary Lymphoid Organs in Mesenchymal Stromal Cell Therapy: More Than Just a Filter.Frontiers in immunology · 2022Review
- Lymph node fibroblastic reticular cells steer immune responses.Trends in immunology · 2021Review
- Lymph node stromal cells: cartographers of the immune system.Nature immunology · 2020Review
- Role of lymph node stroma and microenvironment in T cell tolerance.Immunological reviews · 2019Review
- Assessment of Lymph Node Stromal Cells as an Underlying Factor in Age-Related Immune Impairment.The journals of gerontology. Series A, Biological sciences and medical sciences · 2019Article
- TLR9 signaling in fibroblastic reticular cells regulates peritoneal immunity.The Journal of clinical investigation · 2019Article
- Attenuation of chronic antiviral T-cell responses through constitutive COX2-dependent prostanoid synthesis by lymph node fibroblasts.PLoS biology · 2019Article
- The human lymph node microenvironment unilaterally regulates T-cell activation and differentiation.PLoS biology · 2018Article
- Repetitive ischemic injuries to the kidneys result in lymph node fibrosis and impaired healing.JCI insight · 2018Article
- A Paradoxical Correlation of Cancer-Associated Fibroblasts With Survival Outcomes in B-Cell Lymphomas and Carcinomas.Frontiers in cell and developmental biology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
Abstract
Sepsis is an aggressive inflammatory syndrome and a global health burden estimated to kill 7.3 million people annually. Single-target molecular therapies have not addressed the multiple disease pathways triggered by septic injury. Cell therapies might offer a broader set of mechanisms of action that benefit complex, multifocal disease processes. We describe a population of immune-specialized myofibroblasts derived from lymph node tissue, termed fibroblastic reticular cells (FRCs). Because FRCs have an immunoregulatory function in lymph nodes, we hypothesized that ex vivo-expanded FRCs would control inflammation when administered therapeutically. Indeed, a single injection of ex vivo-expanded allogeneic FRCs reduced mortality in mouse models of sepsis when administered at early or late time points after septic onset. Mice treated with FRCs exhibited lower local and systemic concentrations of proinflammatory cytokines and reduced bacteremia. When administered 4 hours after induction of lipopolysaccharide endotoxemia, or cecal ligation and puncture (CLP) sepsis in mice, FRCs reduced deaths by at least 70%. When administered late in disease (16 hours after CLP), FRCs still conveyed a robust survival advantage (44% survival compared to 0% for controls). FRC therapy was dependent on the metabolic activity of nitric oxide synthase 2 (NOS2) as the primary molecular mechanism of drug action in the mice. Together, these data describe a new anti-inflammatory cell type and provide preclinical evidence for therapeutic efficacy in severe sepsis that warrants further translational study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.